Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

By In The News
March 22, 2019 in The Headlines

Recommended Posts

In The News

Posted March 22, 2019

- Share

Posted March 22, 2019

STOCKHOLM, March 22, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in Europe. Two Phase 3-studies are currently underway in North America and Europe with topline results ...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219982
2. Jaydee
  16830
3. Kip Powick
  12225
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.3k
- Total Posts
  
  559k

Sign In

Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support